PRODUCING a new vaccine is not to prove one’s mettle or for a country to attain “celebrity” status. Trials to study people’s responses to vaccines and any possible adverse effects are key.

To come up with a vaccine against an infectious disease requires sufficient knowledge of the causative agent and its impact on the body. Research updates such knowledge.
In terms of technology, we’ve come a long way since the inoculation methods of centuries past. Numerous vaccine types have emerged, each with its pros and cons.
Vaccine trials
A new vaccine goes through rigorous testing in both animal and human trials. These trials must be thorough, thus they take time.
Clinical trials must show immune responses that are both desired and safe. Small groups of volunteers are tested first, and then, larger groups with conditions similar to those susceptible to the illness in question. Finally, hundreds of thousands of volunteers are tested for vaccine effectiveness and safety. Some receive placebos or alternative interventions for the purpose of result comparison.
Even after a vaccine is approved for use and administered in the community, its effects are continuously monitored.
Adverse event following immunisation
Vaccination is generally safe, but it isn’t flawless. An adverse event following immunisation (AEFI), according to the World Health Organisation (WHO), is an untoward medical occurrence following immunisation that may or may not be caused by the vaccine.
A person’s responses to a vaccine aren’t always predictable, and there could be reactions to, say, a quality defect. These are mostly minor reactions, but there remains the possibility of a severe one. Health workers are educated on how to handle such cases.
AEFI may be related to immunisation errors, which are minimised through proper training on vaccine storage, reconstitution and handling.
The fear of needles could cause some children to vomit, while there are adults who feel light-headed or have fainted when being vaccinated.
And, there are many events falsely attributed to a vaccine simply due to them occurring shortly after the said vaccine is administered.
Vaccine responses
WHO recognises that vaccine acceptance is influenced by dynamic progression and evolving factors (Chen RT & co-workers, 1994).
People embrace vaccination when there’s a vaccine that has proven effective against a disease. Successful vaccination keeps a disease under control, but a tendency to focus on AEFI then arises, with safety issues brought up.
This, in turn, causes vaccination rates to decline. When the focus shifts from the importance of disease prevention to vaccine safety issues, coupled with exaggeration by some quarters, it results in a loss of vaccine confidence. When vaccination rates decline, leading to the absence of herd immunity, we may see a resurgence of diseases.
When this happens, there will be a fresh wave of vaccine confidence. If, at this stage, a new vaccine is available for a disease, the outbreak is controlled once more. And should the vaccine be able to eradicate the disease, then vaccination for the said disease can be halted.
A prudent vaccination programme monitors and quickly addresses adverse events. It should also correct misperceptions by comparing the risks of vaccination to the much greater dangers of diseases.
Payoff
When it comes to the vaccine dilemma, it’s clear that enhancing vaccine acceptance and coverage can be done in a number of ways.
A safe, well-researched vaccine is a handsome reward for our patience. – August 20, 2020.
* Dr Prameela Kannan Kutty is a professor of paediatrics at Universiti Pertahanan Nasional Malaysia.
* This is the opinion of the writer or publication and does not necessarily represent the views of The Malaysian Insight. Article may be edited for brevity and clarity.
Comments
Posted 5 years ago by Janaarthanan Jivananthan · Reply
Posted 5 years ago by Muhammad Asyraf · Reply
Posted 5 years ago by Kaveegeshan Kauthaman · Reply
Posted 5 years ago by Kaveegeshan Kauthaman · Reply
Posted 5 years ago by Aravindar Ravi shankar · Reply
Posted 5 years ago by Eugene Hew · Reply
Posted 5 years ago by Lavanya Sivaji · Reply
Posted 5 years ago by SETEVENRAJ PARANJOTHY · Reply
Posted 5 years ago by Samuel Ting · Reply